InflaRx announces first patient dosed in 2a study of CSU, HS

InflaRx (IFRX) N.V.announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria, CSU, and hidradenitis suppurativa, HS, investigating the Company’s oral C5aR inhibitor, INF904.